Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 111 long-term extension in children with achondroplasia
2015-004004-30Phase 2
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Long-term safety and tolerability.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2015-004004-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004004-30.